Saccharomyces cerevisiae
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA176689 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Dynamic mRNA gene expression following a rapamycin treatment
| PRJNA237817 | ENA
Project description:Gene expression profile during Ebselen treatment in budding yeast
| PRJNA178008 | ENA
Project description:Yeast cells were subjected to different combination of the following perturbations: heat stress, myriocin (ISP1) treatment and lipid (myristate) supplement. Then gene expression and lipidomic data were collected under each experimental condition with triplicates. heat stress, myriocin (ISP1) treatment and lipid (myristate) supplement in triplicates
2012-08-28 | E-GEOD-40399 | biostudies-arrayexpress
Project description:Studies of aging and longevity are revealing how diseases that shorten life can be controlled to improve the quality of life and lifespan itself. Two strategies under intense study to accomplish this goal are rapamycin treatment and calorie restriction. New strategies are being discovered including one that uses low-dose myriocin treatment. Myriocin inhibits the first enzyme in sphingolipid synthesis in all eukaryotes and we showed recently that low-dose myriocin treatment increases yeast lifespan at least in part by down-regulating the sphingolipid-controlled Pkh1/2-Sch9 (ortholog of mammalian S6 kinase) signaling pathway. Here we show that myriocin treatment has global influences and modulates the evolutionarily conserved Snf1/AMPK, PKA and TORC1 signaling pathways to enhance yeast lifespan. These extensive affects of myriocin rival those of rapamycin and calorie restriction. Our studies in yeast along with other studies in mammals reveal the potential of myriocin or related compounds to lower the incidence of age-related diseases in humans. No-myriocin-treated cells and myriocin-treated cells; three biological replicates in each treatment
2014-09-22 | E-GEOD-41362 | biostudies-arrayexpress
Project description:Genome-wide monitoring of gene expression in Saccharomyces cerevisiae upon KP1019 treatment
| PRJNA309174 | ENA
Project description:Gene Expression of MATa yeast segregants (YJM789 X S96) after alpha factor treatment
| PRJNA123987 | ENA
Project description:The expression profile under cooper sulfate treatment
| PRJNA145399 | ENA
Project description:Differential gene expression in CadA strain vs D398A control strain upon 1 μM cadmium treatment
| PRJNA125395 | ENA
Project description:Expression data from Saccharomyces cerevisiae upon honokiol treatment
| PRJNA374888 | ENA
Project description:Studies of aging and longevity are revealing how diseases that shorten life can be controlled to improve the quality of life and lifespan itself. Two strategies under intense study to accomplish this goal are rapamycin treatment and calorie restriction. New strategies are being discovered including one that uses low-dose myriocin treatment. Myriocin inhibits the first enzyme in sphingolipid synthesis in all eukaryotes and we showed recently that low-dose myriocin treatment increases yeast lifespan at least in part by down-regulating the sphingolipid-controlled Pkh1/2-Sch9 (ortholog of mammalian S6 kinase) signaling pathway. Here we show that myriocin treatment has global influences and modulates the evolutionarily conserved Snf1/AMPK, PKA and TORC1 signaling pathways to enhance yeast lifespan. These extensive affects of myriocin rival those of rapamycin and calorie restriction. Our studies in yeast along with other studies in mammals reveal the potential of myriocin or related compounds to lower the incidence of age-related diseases in humans.
2014-09-22 | GSE41362 | GEO